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Background. The aims of this study were to determine the
prevalence of early nephropathy in patients with type 2 diabetes
mellitus (DM2) attending primary care medical units and to
identify risk factors for nephropathy in this population.
Method. Seven hundred fifty-six patients with DM2 attend-
ing 3 primary care medical units were randomly selected. In
a first interview, an albuminuria dipstick and a detailed clinical
examination were performed, and a blood sample was obtained.
If the albuminuria dipstick was positive, then a 24-hour urine
collection was obtained within the next 2 weeks to quantify the
albuminuria. In the blood sample, glucose, creatinine, and lipids
were determined. Glomerular filtration rate was calculated us-
ing the Modification of Diet in Renal Disease Study equation.
Demographics and medical history were recorded from clinical
examination and medical charts.
Results. Prevalence of early nephropathy (EN) was 40%, nor-
mal function (NF) was found in 31%, and overt nephropathy
(ON) in 29%. Patients with more severe kidney damage were
older (NF: 54 ± 10; EN: 60 ± 11; ON: 63 ± 10 years, P < 0.05)
and had a higher proportion of illiteracy (NF: 11%, EN: 17%;
ON: 25%, P < 0.05). The more severe the nephropathy, the
longer the median duration of DM2 (NF: 6.0; EN: 7.0; ON: 11.0
years; P < 0.05); the higher the frequency of hypertension (NF:
38%; EN: 52%; ON: 68%; P < 0.05); and the higher the systolic
blood pressure (NF: 126 ± 21; EN: 130 ± 19; ON: 135 ± 23
mm Hg; P < 0.05). Both nephropathy groups had a significantly
higher proportion of family history of nephropathy (NF: 4%;
EN: 9%; ON: 13%) and a higher frequency of cardiovascular
disease (NF: 5%; EN: 12%; ON: 25%), whereas only patients
with ON had peripheral neuropathy (NF: 21%; EN: 22%; ON:
43%) and retinopathy (NF: 12%; EN: 18%; ON: 42%) more
frequently than others. Fasting glucose was poorly controlled in
all groups (NF: 186 ± 70; EN: 173 ± 62; ON: 183 ± 73 mg/dL).
Large body mass index (NF: 29.3 ± 5.3; EN: 29.7 ± 5.6; ON: 29.6
± 5.5 kg/m2), smoking (NF: 45%; EN: 43%; ON: 44%), and alco-
holism (NF: 29%, EN: 29%; ON: 26%) were frequently found
in this population, although there were no significant differ-
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ences. In the multivariate analysis, only age, duration of DM2,
and presence of retinopathy, hypertension, and cardiovascular
disease were significantly associated with nephropathy.
Conclusions. Two thirds of Mexican patients with DM2 at-
tending primary health care medical units had nephropathy,
40% of whom were at an early stage of the disease. Many mod-
ifiable and nonmodifiable risk factors were present in these
patients, but the most significant predictors for nephropathy
are older age, longer duration of diabetes, and the presence of
retinopathy, hypertension, and cardiovascular disease.
Resumen
Antecedentes. Los objetivos del presente estudio fueron el
determinar la prevalencia de nefropatı´a temprana en diabetes
mellitus tipo 2 (DM2) de pacientes en clı´nicas de atencio´n pri-
maria, ası´ como el identificar factores de riesgo de nefropatı´a
en esta poblacio´n.
Me´todos. 756 pacientes con DM2 que acudı´an a 3 clı´nicas de
atencio´n primaria fueron seleccionados al azar. En la primera
visita se realizo´ un examen clı´nico detallado, se detecto´ la pres-
encia de albuminuria con cinta reactiva y se obtuvo una mues-
tra de sangre. A los pacientes con tira reactiva positiva, se les
cuantifico´ albuminuria en una muestra de orina de 24 horas. Se
determinaron niveles de glucosa, creatinina y lı´pidos en sangre.
La velocidad de filtracio´n glomerular (VFG) se estimo´ medi-
ante la ecuacio´n del Estudio de Modificacio´n de Dieta en la
Enfermedad Renal (MDRD). La informacio´n demogra´fica y
la historia clı´nica se obtuvieron del expediente me´dico y del
examen clı´nico.
Resultados. La prevalencia de nefropatı´a temprana (NT) fue
del 40%, funcio´n normal (FN) del 31% y nefropatı´a establecida
(NE) del 29%. Aquellos pacientes con mayor dan˜o renal tenı´an
ma´s edad (FN: 54 ± 10; NT: 60 ± 11; NE: 63 ± 10 an˜os, P < 0.05) y
mayor analfabetismo (FN: 11%, NT: 17%, NE: 25%, P < 0.05).
Entre ma´s dan˜o renal, mayor la duracio´n media de la DM2 (FN
6.0; NT:7.0, NC: 11.0 an˜os, P < 0.05), mayor la frecuencia de
hipertensio´n (FN: 38%, NT: 52%; NE: 68%, P < 0.05), y mayor
la elevacio´n de la presio´n arterial sisto´lica (FN: 126 ± 21; NT:
130 ± 19; NE: 135 ± 23 mm Hg, P < 0.05). Los grupos con
nefropatı´a tenı´an un porcentaje alto de antecedentes familiares
de enfermedad renal (FN: 4%; NT: 9%; NE: 13%) y una mayor
frecuencia de enfermedad cardiovascular (FN:5%; NT: 12%;
NE: 25%), mientras que so´lo los pacientes con NC presentaban
una mayor frecuencia de neuropatı´a perife´rica (FN: 21%; NT:
22%; NE: 43%) y retinopatı´a (FN: 12%; NT: 18%; NE: 42%)
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que los otros grupos. Todos los grupos presentaron un pobre
control de la glucemia en ayunas (FN: 186 ± 70; NT: 173 ± 62;
NE: 183 ± 73). Un elevado ı´ndice de masa corporal (FN:29.3
± 5.3; NT: 29.7 ± 5.6; NE: 29.6 ± 5.5 kg/m2) tabaquismo (FN:
45%; NT: 43%, NE: 44%) y alcoholismo (FN: 29%; NT: 29%;
NE: 26%) se observaron frecuentemente, sin existir diferencias
importantes entre los grupos. En el ana´lisis multivariado, sola-
mente la edad, la duracio´n de la DM2, ası´ como la presencia de
retinopatı´a, hipertensio´n arterial y enfermedad cardiovascular,
predijeron la presencia de nefropatı´a.
Conclusiones. Dos terceras partes de los pacientes con DM2
que acudieron a clı´nicas de atencio´n primaria presentaron ne-
fropatı´a, y en el 40% de ellos correspondio´ a un estadio tem-
prano. Numerosos factores, modificables y no modificables, es-
tuvieron presentes en estos pacientes, pero los ma´s importantes
predictores de nefropatı´a fueron mayor edad, mayor duracio´n
de la diabetes, ası´ como la presencia de retinopatı´a, hipertensio´n
y enfermedad cardiovascular.
Recent data from many parts of the world have demon-
strated a dramatic increase in prevalence and incidence
of end-stage renal disease (ESRD) [1–3]. Most individu-
als at earlier stages of chronic kidney disease (CKD) have
been largely undiagnosed and/or undertreated [4, 5]. In
spite of all the improvements in diagnosis and treatment,
ESRD is a major health problem associated with consid-
erable morbidity, mortality, poor quality of life, and high
costs. If ESRD continues to increase, it is likely that no
health system will be able to face its costs. Therefore, it
is necessary to emphasize prevention (primary and sec-
ondary). To slow progression of kidney failure, prevent
consequences of CKD, and decrease associated cardio-
vascular (and all cause) mortality, it is crucial to detect
patients with CKD early in its course and to optimize
their care.
American [6, 7] and European [8] health organiza-
tions recommend periodic evaluation of all individuals
at increased risk for kidney disease. Appropriate mea-
surement and interpretation of urine albumin and serum
creatinine in all individuals at increased risk for CKD,
such as patients with diabetes and hypertension, could
identify a large number of patients in earlier stages of
kidney disease.
In our setting, type 2 diabetes mellitus (DM2) is the
leading cause of ESRD (40%) [9]; however, published
data about the prevalence of nephropathy in this high-
risk population are scarce. Therefore, our study was de-
signed to determine the prevalence and characteristics of
early nephropathy in patients with DM2 attending pri-
mary health care units and to identify risk factors for
nephropathy in this population.
PATIENTS AND METHODS
In Jalisco, a western state of Mexico, 44% of the pop-
ulation (2,827,000) is covered under the social security
health system, and of this number, 93% is under the care
of the Mexican Institute of Social Security (IMSS). In
Guadalajara, this institution has 24 primary care med-
ical units. Three of these medical units were randomly
selected for the present study. From the DM2 population
attending these 3 primary care units, we randomly se-
lected 756 patients, aged 18 years and older; this sample
size was capable of detecting conditions with a preva-
lence of at least 20% and with an estimation error of 5%.
DM2 was diagnosed in all these patients by their fam-
ily doctors, using the diagnostic criteria of the American
Diabetes Association. Patients with conditions resulting
in transient proteinuria, such as standing position, uri-
nary tract infections, exercise, menstruation, and so on,
were excluded. No patient had a previous diagnosis of
nephropathy.
In a first interview, a dipstick urinalysis was performed
on a first voided morning urine sample. The patient was
excluded if proteinuria was present; if proteinuria was ab-
sent, an albuminuria dipstick (Micral-test II; Roche Di-
agnostics GmbH, Mannheim, Germany) was performed.
In addition, a detailed clinical examination, including
neurologic and eye examinations with direct ophthal-
moscopy, was performed, and a blood sample was ob-
tained. The blood sample was tested for glucose, crea-
tinine, cholesterol, and triglycerides by usual methods.
If the albuminuria dipstick was positive, then a 24-hour
urine collection was obtained within the next 2 weeks to
quantitatively measure microalbuminuria by nephelom-
etry (Behring Nephelometer Analyzer Ii; Behring Diag-
nostics GmbH, Marburg, Germany). All laboratory mea-
surements were performed in the Central Laboratory of
the Hospital de Especialidades, Centro Me´dico Nacional
de Occidente, IMSS. Demographic data and medical his-
tory were recorded from clinical examination and medi-
cal charts.
Definitions
CKD was classified according to the Kidney Disease
Outcomes Quality Initiative guidelines [6]. We defined
early nephropathy as the presence of microalbuminuria
(MIA, 30–300 mg/day) even with a normal glomerular
filtration rate (GFR), or the presence of a mildly de-
creased GFR (60–89 mL/min/1.73 m2) with or without
MIA. Overt nephropathy was defined as the presence of
macroalbuminuria (MAA, >300 mg/day) and/or a mod-
erate or severe decrease in GFR <60 mL/min/1.73 m2).
Normal renal function was defined as the presence of
a GFR >90 mL/min/1.73 m2 and without albuminuria.
GFR was estimated using the simplified equation of the
Modification of Diet in Renal Disease Study [6, 11].
Patients were classified as smokers if they had smoked
>100 cigarettes in their lifetime and continued to smoke
at the time of the study. Alcoholism was defined as at
least one episode of alcohol intoxication during the pre-
vious month. Hypertension was defined as a blood pres-
sure >140/90 mm Hg or a history of antihypertensive
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Table 1. Prevalence of CKD and albuminuria in 756 Mexican patients with DM2
Albuminuria within each level of renal function
GFR mL/min/1.73m2 Prevalence No MIA MIA 30–300 mg/day MIA >300 mg/day Stage of CKD
≥90 37.1 82.3 12.5 5.2 1
60–89 38.4 73.7 19.2 7.1 2
30–59 23.8 51.1 27.6 21.3 3
15–29 0.7a 20.0 20.0 60.0 4
Total% 100 71.1 18.7 10.1
Abbreviations are: CKD, chronic kidney disease; DM2, type 2 diabetes mellitus; GFR, glomerular filtration rate; MIA, microalbuminuria.
aCalculated with a very small number of patients (N 5).
Dark shaded area indicates individuals with CKD. Patients within dotted lines had early nephropathy, whereas patients outside dotted lines, but within the shaded
area, had overt nephropathy.
treatment. Cardiovascular disease was considered
present if previously documented in medical records, or
if there was a presence of heart failure, myocardial infarc-
tion, arrhythmias, electrocardiogram abnormalities, or
evidence of cerebrovascular accidents at the time of clin-
ical examination. Retinopathy was defined as the pres-
ence of background or proliferative lesions on clinical
examination, or if previously documented in the medi-
cal records. Peripheral neuropathy was diagnosed if the
patient failed to detect the presence of a 10 g monofila-
ment (Neuropen, Owen Mumford, Ltd., Oxford, United
Kingdom) applied on the foot 3 out of 5 times.
Statistical analysis
Data are expressed as mean ± standard deviation,
median (percentiles 25%–75%), or percentages as ap-
propriate. Comparisons between groups were made by
analysis of variance and chi-square. Multivariate analy-
sis to identify factors predicting early nephropathy was
performed by discriminant analysis. A P value <0.05 was
accepted as significant, but preferably the exact value was
shown.
RESULTS
Of the 756 patients assessed, 467 (62%) were women.
Less than 1% had severely decreased GFR, and none
had ESRD (Table 1). Seventy-one percent had no al-
buminuria, 19% had MIA, and 10% had MAA. From
those with a normal GFR, over 80% had no albuminuria;
however, the lower the GFR, the greater the proportion
of patients with albuminuria. The proportion of patients
with early nephropathy was 40%, whereas normal func-
tion was found in 31% and overt nephropathy in 29% of
patients (Fig. 1).
Patients with more severely diminished renal func-
tion were older and had a higher proportion of illiteracy
(Table 2). On the other hand, there were no differences
with respect to gender, smoking, or alcoholism between
groups; notwithstanding, smoking and alcohol consump-
tion were very frequent in all groups.
The more severe the nephropathy, the longer the du-
ration of DM2, the higher the frequency of hyperten-
Normal function
Early nephropathy
Overt nephropathy
31%
40%
29%
Fig. 1. Percentage prevalence of nephropathy in 756 patients with type
2 diabetes mellitus.
Table 2. Demographic data according to the presence of
nephropathy in patients with DM2
Variable Normal Early nephropathy Overt nephropathy
Age years 54 ± 10 60 ± 11a 63 ± 10a,b
Male sex N 79 (35%) 121 (41%) 76 (36%)
Smoking N 100 (45%) 127 (43%) 93 (44%)
Alcoholism N 65 (29%) 85 (29%) 55 (26%)
Illiteracy N 24 (11%) 49 (17%) 54 (25%)
Abbreviation is: DM2, type 2 diabetes mellitus.
aP < 0.05 vs. normal.
bP < 0.05 vs. early nephropathy.
sion, and the higher the systolic blood pressure (Table 3).
Patients with nephropathy had significantly longer dura-
tion of hypertension, higher proportion of family history
of nephropathy, and higher frequency of cardiovascular
disease than those with normal function. Only patients
with overt nephropathy had peripheral neuropathy and
retinopathy more frequently diagnosed than others. Even
though there was no difference in mean body mass index
between groups, most were near the obesity range.
From the serum biochemical data (Table 4), the fasting
glucose was poorly controlled in all groups. Mean choles-
terol was within normal range, whereas triglycerides were
above normal range in all groups. As expected, serum cre-
atinine, albuminuria, and GFR were significantly worse
in patients with early and overt nephropathy than in pa-
tients with normal function.
In the multivariate analysis (Table 5), older age,
longer duration of DM2, and presence of retinopathy,
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Table 3. Clinical data according to the presence of nephropathy in patients with DM2
Variable Normal Early nephropathy Overt nephropathy
Family history of nephropathy N 9 (4%) 27 (9%)a 27 (13%)a
Family history of hypertension N 94 (42%) 99 (34%) 69 (32%)
Duration of DM2 years 6.0 (3.0–11.0) 7.0 (2.1–13.0) 11.0 (5.0–17.0)a,b
Hypertension N 85 (38%) 153 (52%)a 145 (68%)a,b
Duration of hypertension years 4.0 (1.7–9.5) 6.0 (3.0–12.0)a 6.0 (2.0–15.0)a
Systolic BP mm Hg 126 ± 21 130 ± 19 135 ± 23a,b
Diastolic BP mm Hg 74 ± 10 76 ± 11 76 ± 11
Body mass index kg/m2 29.3 ± 5.3 29.7 ± 11 29.6 ± 5.5
Cardiovascular disease N 11 (5%) 35 (12%) 54 (25%)a
Peripheral neuropathy N 47 (21%) 64 + (22%) 92 (43%)a,b
Retinopathy N 26 (12%) 54 + (18%) 89 (42%)a
Abbreviations are: DM2, type 2 diabetes mellitus; BP, blood pressure.
aP < 0.05 vs. normal.
bP < 0.05 vs. early nephropathy
Table 4. Biochemical data according to the presence of nephropathy
in patients with DM2
Variable Normal Early nephropathy Overt nephropathy
Glucose 186 ± 70 173 ± 62a 183 ± 73
mg/dL
Creatinine 0.67 ± 0.13 0.84 ± 0.16a 1.09 + 0.31a,b
mg/dL
Cholesterol 199 ± 50 202 ± 69 202 ± 69
mg/dL
Triglycerides 201 (143–285 182 (137–261) 195 (144–253)
mg/dL
Albuminuria 9.8 (6.0–17.6) 38.0 (10.8–92.4)a 163.0 (19.5–712)a,b
mg/day
GFR mL/min/ 112.5 ± 20.3 80.0 ± 16.2a 55.0 ± 18.1a,b
1.73 m2
Abbreviations are: DM2, type 2 diabetes mellitus; GFR, glomerular filtration
rate.
aP < 0.05 vs. normal.
bP < 0.05 vs. early nephropathy.
Table 5. Predictive factors for nephropathy in patients with DM2 by
discriminant analysis (dp 175, P < 0.0001)
Variable F P value
Age years 18.8 <0.0001
Presence of retinopathy 13.0 <0.0001
Presence of hypertension 8.7 <0.0001
Presence of cardiovascular disease 7.0 <0.0001
Duration of DM2 5.4 <0.0001
Abbreviations are: DM2, type 2 diabetes mellitus; dp, chi-square; F, statistic.
hypertension, and cardiovascular disease significantly
and independently predicted with nephropathy.
DISCUSSION
National surveys have shown a marked increase of non-
communicable chronic diseases (including diabetes mel-
litus, hypertension, and obesity) in Mexico [12]. Patients
with DM and those with Hispanic origin have been con-
sidered at increased risk for CKD [6]; nonetheless, data
about prevalence of early nephropathy in this high-risk
population in Mexico and other parts of Latin America
are scarce. The prevalence of MIA and MAA in DM2
found in the present study is similar to that reported in
non-Hispanic studies [13–18]. In a previous study, MIA
was reported in about 50% of Mexican patients with di-
abetes [19]; however, in that study, transitory causes of
MIA were not excluded, and persistent MIA was deter-
mined in only a relatively small sample of patients.
The natural history of nephropathy is less well de-
scribed in DM2 than in type 1 diabetes mellitus (DM1).
The proportion of patients with DM2 who develop MIA
or MAA is substantial [13–18]. However, the ability of al-
buminuria to predict nephropathy in DM2 may be lower
than in DM1 because of several factors, including the as-
sociation of albuminuria with cardiovascular death [20]
(ie, death before development of overt nephropathy) and
the presence of albuminuria before onset of diabetes
[13]. Therefore, to improve detection and management
in patients with DM2, we agree with clinical guidelines
[6] that CKD be defined as the presence of albuminuria
and level of GFR. There was a high prevalence of early
(40%) and overt nephropathy (29%) in this study. In the
Third National Health and Nutrition Examination Sur-
vey study, patients with diabetes had a 40% prevalence
of mildly decreased GFR, a 14% prevalence of moder-
ately decreased GFR, and a 1% prevalence of severely
decreased GFR [21], whereas the prevalence of MIA
in this kind of patient was 29% [22]. However, to the
best of our knowledge, no previous study had determined
the presence of early nephropathy in patients with DM2
based on both albuminuria and the level of GFR. Be-
cause several interventions may reduce the risk of disease
progression and prevent cardiovascular complications in
diabetic nephropathy, early detection in this group of pa-
tients should be emphasized.
Many modifiable and nonmodifiable risk factors for
nephropathy and other complications of diabetes [17,
18, 24–28] were present in our study population and
other studies in Mexican patients with DM2 [19, 29].
In contrast with other studies [17, 27, 28], we found no
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predominance of male patients with nephropathy. There
was a high proportion of smoking and alcohol consump-
tion in all patients, but none was significantly associated
with nephropathy. In the group with normal renal func-
tion, illiteracy was similar to the mean reported in the
general Mexican population, [30], but it increased as the
diagnosed nephropathy increased in severity; this could
reflect a negative effect of poverty on the development
of nephropathy.
Family history of nephropathy, but not of hyperten-
sion, was more common in patients with nephropathy
than in patients with normal function. This may suggest
the role of genetic and familial factors involved in the de-
velopment of nephropathy of some patients with DM2.
Hypertension seems to play an important role in the
nephropathy of DM2 [18, 24–26, 28]; the higher the
systolic blood pressure and the longer the duration of
hypertension, the more severe the nephropathy. It is in-
teresting to note, however, that blood pressure seemed
to be reasonably well controlled in patients attending the
primary health care unit. Mean body mass index was al-
most in the obesity range in patients in the present study;
similar findings have been found in other Mexican se-
ries of patients with DM2 [29]. Peripheral neuropathy
was more frequently seen in patients with more severe
nephropathy, which is consistent with findings in other
studies [27].
A lack of optimal metabolic control in all groups is
evident in this study, and it also seems to be a common
finding in other Mexican studies of patients with DM2
[19, 29]. This is particularly worrisome, because a lack of
glycemic control has been associated with progression of
diabetic nephropathy [7, 28].
From the risk factors studied in this population, the
only significant predictors of nephropathy in the multi-
variate analysis were older age, longer duration of di-
abetes, and the presence of retinopathy, hypertension,
and cardiovascular disease. Patients with more severe
nephropathy tended to be older, and duration of diabetes
was significantly longer in those with overt nephropa-
thy; these findings are in agreement with several stud-
ies previously reported in other racial and ethnic groups
[17, 18, 24, 31]. The predictive association of retinopa-
thy and nephropathy in patients with DM2 found in the
present study is consistent with findings in other studies
[17]. It seems to be broadly accepted that retinopathy
predicts nephropathy; in fact, it has been proposed that
in patients with DM2, a clinical diagnosis of nephropa-
thy can be made if simplex or proliferative retinopathy is
found [32]. The relationship between high blood pressure
and cardiovascular disease with renal disease in DM2, as
found in the present work, seems to be consistent with
other studies as well [18, 24, 25, 33, 34].
In conclusion, two thirds of Mexican patients with
DM2 attending primary health care medical units had
nephropathy, and in 40% it corresponded with an early
stage. Many modifiable and nonmodifiable risk factors
are present in these patients, but the most significant pre-
dictors for nephropathy are older age, longer duration
of diabetes, and the presence of retinopathy, hyperten-
sion, and cardiovascular disease. The necessity of early
detection of nephropathy in patients with DM2 cannot be
overemphasized. By these means, health care providers
can institute beneficial therapy interventions to reduce
the risk of disease progression and prevent cardiovascu-
lar complications.
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